葫芦素B通过诱导DNA损伤依赖性细胞周期阻滞抑制肝细胞癌进展
该研究探讨葫芦素B(CuB)抑制肝细胞癌(HCC)的作用与机制,采用Huh7、Hep3B和Hepa1/6肝癌细胞及Hepa1/6荷瘤BALB/c小鼠模型。CuB显著抑制细胞生长并诱导G2/M期阻滞而不直接引起细胞死亡,机制涉及ATM依赖的p53-p21-CDK1和CHK1-CDC25C通路,动物实验验证CuB抑制肿瘤生长。
要点
- CuB抑制肝癌细胞生长并诱导G2/M期阻滞,不直接触发凋亡或坏死。
- CuB通过ATM-p53-p21-CDK1和CHK1-CDC25C通路发挥细胞周期阻滞作用。
- 动物实验显示CuB抑制Hepa1/6荷瘤小鼠肿瘤生长,降低PCNA和γ-H2AX表达。
核心结论
- CuB通过诱导DNA损伤依赖性细胞周期阻滞有效抑制HCC进展,不直接触发细胞死亡。
- 该作用通过ATM依赖的p53-p21-CDK1和CHK1-CDC25C信号通路实现。
- CuB可能作为抗HCC药物,但需独立研究确认及后续各期临床试验验证。
研究设计与样本
- 体外实验使用Huh7、Hep3B和Hepa1/6肝癌细胞系。
- 采用CCK-8和克隆形成实验检测CuB对肝癌细胞的抑制作用。
- 采用Calcein-AM/PI染色和LDH测定评估细胞死亡,流式细胞术检测凋亡和细胞周期。
- 采用蛋白质组学、Western blotting和RNA干扰探索潜在机制。
- 动物实验使用Hepa1/6荷瘤BALB/c小鼠验证体外实验结果。
主要发现
- CuB显著抑制Huh7、Hep3B和Hepa1/6细胞生长并触发G2/M期细胞周期阻滞,不导致细胞死亡尤其凋亡。
- 敲低CuB靶点IGF2BP1未逆转CuB诱导的细胞周期阻滞。
- CuB增强p-ATM和γ-H2AX水平,增加p53和p21水平,降低CDK1表达,提高p-CHK1水平并抑制CDC25C蛋白水平。
- DNA保护剂甲基普罗胺(MPA)部分取消上述现象。
- 动物实验中CuB显著抑制Hepa1/6荷瘤BALB/c小鼠肿瘤生长,降低肿瘤组织PCNA和γ-H2AX表达,未改变TUNEL水平。
临床怎么用
- CuB作为葫芦素片的主要活性成分,已广泛用于临床多种恶性肿瘤尤其HCC的治疗。
- 本研究提示CuB通过DNA损伤依赖性细胞周期阻滞发挥抗HCC作用,不直接诱导细胞死亡。
- CuB作为抗HCC药物需在独立研究确认及完成1、2、3、4期临床试验后方可应用。
局限性
- 研究结论需独立研究确认。
- 需完成更多临床1、2、3、4期试验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The mortality rate of liver cancer ranks third in the world, and hepatocellular carcinoma (HCC) is a malignant tumor of the digestive tract. Cucurbitacin B (CuB), a natural compound extracted from Cucurbitaceae spp., is the main active component of Chinese patent medicine the Cucurbitacin Tablet, which has been widely used in the treatment of various malignant tumors in clinics, especially HCC. PURPOSE: This study explored the role and mechanism of CuB in the suppression of liver cancer progression. METHODS: Cell Counting Kit-8 (CCK-8) and colony formation assays were used to detect the inhibitory function of CuB in Huh7, Hep3B, and Hepa1/6 hepatoma cells. Calcein-AM/propidium iodide (PI) staining and lactate dehydrogenase (LDH) measurement assays were performed to determine cell death. Mitochondrial membrane potential (Δψm) was measured, and flow cytometry was performed to evaluate cell apoptosis and cell cycle. Several techniques, such as proteomics, Western blotting (WB), and ribonucleic acid (RNA) interference, were utilized to explore the potential mechanism. The animal experiment was performed to verify the results of in vitro experiments. RESULTS: CuB significantly inhibited the growth of Huh7, Hep3B, and Hepa1/6 cells and triggered the cell cycle arrest in G2/M phage without leading to cell death, especially apoptosis. Knockdown of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1), a target of CuB, did not reverse CuB elicited cell cycle arrest. CuB enhanced phosphorylated ataxia telangiectasia mutated (p-ATM) and phosphorylated H2A histone family member X (γ-H2AX) levels. Moreover, CuB increased p53 and p21 levels and decreased cyclin-dependent kinase 1 (CDK1) expression, accompanied by improving phosphorylated checkpoint kinase 1 (p-CHK1) level and suppressing cell division cycle 25C (CDC25C) protein level. Interestingly, these phenomena were partly abolished by a deoxyribonucleic acid (DNA) protector methylproamine (MPA). Animal studies showed that CuB also significantly suppressed tumor growth in BALB/c mice bearing Hepa1/6 cells. In tumor tissues, CuB reduced the expression levels of proliferating cell nuclear antigen (PCNA) and γ-H2AX but did not change the terminal deoxynucleotidyl transferase deoxyuridine triphosphate (dUTP) nick-end labeling (TUNEL) level. CONCLUSION: This study demonstrated for the first time that CuB could effectively impede HCC progression by inducing DNA damage-dependent cell cycle arrest without directly triggering cell death, such as necrosis and apoptosis. The effect was achieved through ataxia telangiectasia mutated (ATM)-dependent p53-p21-CDK1 and checkpoint kinase 1 (CHK1)-CDC25C signaling pathways. These findings indicate that CuB may be used as an anti-HCC drug, when the current findings are confirmed by independent studies and after many more clinical phase 1, 2, 3, and 4 testings have been done.
引用
- Li QZ, Chen YY, Liu QP, et al. Cucurbitacin B suppresses hepatocellular carcinoma progression through inducing DNA damage-dependent cell cycle arrest. Phytomedicine. 2023. PMID: 38412667. doi:10.1016/j.phymed.2023.155177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。